Citius pharmaceuticals details near-term milestones for late-stage candidates

Multiple catalysts for potentially transformative assets in second half of 2024 strong momentum expected from positive topline results of phase 3 mino-lok® trial, commercialization of lymphir™ if approved first-and-only advantage for mino-lok with no current fda-approved or investigational products; lymphir expected to be additive to current treatment options with mechanism of action supporting market advantage financial platform and pending oncology spin-off support pipeline development and investment in long-term growth clinical and operational achievements offer powerful levers for value creation national sales director onboarded to recruit and lead the sales organization in preparation for anticipated launch of lymphir cranford, n.j. , july 10, 2024 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced expected milestones in the second half of calendar 2024 and recapped key achievements year-to-date leonard mazur, chairman and ceo of citius stated, "our solid execution since the beginning of the year sets us up for potentially transformative catalysts in the coming months.
CTXR Ratings Summary
CTXR Quant Ranking